The stock of Edwards Lifesciences Corp (NYSE: EW) has increased by 0.18 when compared to last closing price of 65.37.Despite this, the company has seen a loss of -1.64% in its stock price over the last five trading days. zacks.com reported 2024-10-03 that Edward Lifesciences’ Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio of 26.95x that is above its average ratio. Additionally, the 36-month beta value for EW is 1.12. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 7 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EW is 592.02M and currently, short sellers hold a 1.92% ratio of that float. The average trading volume of EW on October 07, 2024 was 6.76M shares.
EW’s Market Performance
EW’s stock has seen a -1.64% decrease for the week, with a -0.80% drop in the past month and a -28.69% fall in the past quarter. The volatility ratio for the week is 2.43%, and the volatility levels for the past 30 days are at 2.93% for Edwards Lifesciences Corp The simple moving average for the last 20 days is -1.95% for EW’s stock, with a simple moving average of -19.29% for the last 200 days.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Jefferies repeating the rating for EW by listing it as a “Hold.” The predicted price for EW in the upcoming period, according to Jefferies is $70 based on the research report published on September 18, 2024 of the current year 2024.
EW Trading at -1.34% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.87% of loss for the given period.
Volatility was left at 2.93%, however, over the last 30 days, the volatility rate increased by 2.43%, as shares sank -1.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.70% upper at present.
During the last 5 trading sessions, EW fell by -1.64%, which changed the moving average for the period of 200-days by -12.54% in comparison to the 20-day moving average, which settled at $66.73. In addition, Edwards Lifesciences Corp saw -14.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from BOBO DONALD E JR, who sale 5,000 shares at the price of $66.77 back on Sep 11 ’24. After this action, BOBO DONALD E JR now owns 46,936 shares of Edwards Lifesciences Corp, valued at $333,826 using the latest closing price.
Chopra Daveen, the CVP, TMTT of Edwards Lifesciences Corp, sale 1,250 shares at $69.95 during a trade that took place back on Aug 20 ’24, which means that Chopra Daveen is holding 29,333 shares at $87,438 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.25. The total capital return value is set at 0.18. Equity return is now at value 21.35, with 15.44 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 58.31.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 6.42. The receivables turnover for the company is 7.19for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In conclusion, Edwards Lifesciences Corp (EW) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
